MAPK14
Mitogen-activated protein kinase 14
As of the edition of 20 October 2026, MAPK14 (mitogen-activated protein kinase 14, UniProt Q16539) has 24 drugs tested at it and 18 companies on the list, 17 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q16539
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 267
- Disease areas
- Bones, joints and muscles; Lungs and airways; Immune system; Skin and connective tissue; Nervous system; Heart and blood vessels; Mental health; Digestive system
- Registered trials of its drugs
- 118
Drugs at this target
| Status | Count |
|---|---|
| Went quiet | 15 |
| Stopped | 7 |
| Status not established | 2 |
| Total | 24 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Losmapimod | Stopped | Phase 3 | none listed |
| PH-797804 | Stopped | Phase 2 | none listed |
| Dilmapimod | Went quiet | Phase 2 | none listed |
| Neflamapimod | Stopped | Phase 2 | none listed |
| ARRY-797 | Went quiet | Phase 2 | none listed |
| Talmapimod | Went quiet | Phase 2 | none listed |
| Acumapimod | Went quiet | Phase 2 | none listed |
| Ralimetinib | Went quiet | Phase 2 | none listed |
| Semapimod | Went quiet | Phase 2 | none listed |
| AZD-7624 | Went quiet | Phase 2 | none listed |
| Doramapimod | Stopped | Phase 2 | none listed |
| Itx-5061 free base | Stopped | Phase 2 | none listed |
12 of 24 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 17 |
| Undetermined | 1 |
| Total on the list | 18 |
| Company | Route |
|---|---|
| Bristol Myers Squibb | Route A |
| GSK | Route A |
| Takeda | Route A |
The other 15 companies at MAPK14
In the product18 companies in all; 15 are not named here, and no score is.
See the 18 companies at MAPK14, ranked, with the facts behind eachRequest access. Nothing is shown until you do.